pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
116
stories
5h
Significant stock movers of September: Viking soars, Longeveron slides
biospace
3d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Varda raises $251M to leverage gravity in space for drug production
biospace
4d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
6d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
6d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
7d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
7d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
7d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
11d
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
11d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
11d
Merck’s return to ophthalmology snags first success
endpoints
11d
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
18d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
20d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
21d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
21d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
21d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
22d
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
24d
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
25d
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
26d
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
26d
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
26d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
27d
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
27d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
27d
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
biospace
27d
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
biospace
← prev
page 1 of 4
next →
